|Registry of biomedical companies:
   [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 504 active entries
3475-S Edison Way
Menlo Park, CA
United States of America, California
Developer of therapeutic protein conjugates with enhanced potency and decreased immunogenicity.
Specializing in receptor-binding ligands and enzymes.
Provider of proprietary technology for cost-effective production of unusually homogeneous conjugates with lower immunoreactivity than conventional PEG conjugates.
Licensors of Krystexxa(R) (formerly Puricase(R)) brand of pegloticase to Savient Pharmaceuticals, Inc. Krystexxa was approved for marketing in the U.S. during 2010 for treatment of adults with chronic gout that is refractory to xanthine oxidase inhibitors and was approved for marketing in the EU during January 2013. Krystexxa is currently licensed exclusively to Horizon Therapeutics plc and is marketed in the United Staes by Horizon (NASDAQ: HZNP). Sales and marketing licenses are available for ex-U.S. territories.
Patent and trademark owners of PharmaPEG(R) for avoiding immune responses to methoxyPEG in PEGylated therapeutic proteins and liposomes and PuriPEG(R) for more homogeneous mPEG conjugates.
Inquire about consulting services and patent licenses available in your fields of interest. See www.mvpharm.com for additional details.
Strictest confidentiallity can be assured.
Last update of this entry: August 28, 2019